MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistanceAmy Farrell, Rosalie C. Sears, Owen J. Sansom et al.|Nature Communications|2017Cited by 159
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i> -Amplified Breast CancersMeghan M. Joly, Rebecca S. Cook, Donna J. Hicks et al.|Cancer Research|2016Cited by 83
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and SurvivalThomas A. Werfel, Craig L. Duvall, Shan Wang et al.|Cancer Research|2018Cited by 82
Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasisMeghan M. Joly, Rebecca S. Cook, Michelle M. Williams et al.|Breast Cancer Research|2017Cited by 79
Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics DataJill M. Pulley, David M. Aronoff, Jillian P. Rhoads et al.|The Annual Review of Pharmacology and Toxicology|2019Cited by 59